

# Long-Term Follow-Up of Infants Exposed to Antiretroviral Drugs

Updated: January 31, 2023

Reviewed: January 31, 2023

Panel's Recommendations
<ul style="list-style-type: none"><li>Children with perinatal exposure to HIV and antiretroviral (ARV) drugs who develop significant organ system abnormalities of unknown etiology, particularly of the nervous system or heart, should be evaluated for potential metabolic dysfunction (CIII).</li><li>It is important that the long-term medical record of a child without HIV includes information about perinatal HIV and ARV exposure (BIII).</li></ul>
<i>Rating of Recommendations: A = Strong; B = Moderate; C = Optional</i>
<i>Rating of Evidence: I = One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II = One or more well-designed, nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion</i>

Beginning in the 1990s, long-term monitoring and outcomes studies, as well as ongoing surveillance and research, have been conducted to assess whether *in utero* exposure to antiretroviral (ARV) drugs may pose later risks to children's health. These studies include children without HIV infection who are born to mothers with HIV (e.g., the Pediatric AIDS Clinical Trial Group [PACTG] Late Outcomes Study and the Surveillance Monitoring for ART Toxicities [SMARTT] study from the Pediatric HIV/AIDS Cohort Study [PHACS]). Participation of children and their parents in observational studies provides an essential contribution to the research needed to monitor and identify long-term health outcomes following *in utero* HIV and ARV exposure. Available evidence does not permit definitive conclusions about whether *in utero* exposure to HIV and ARV agents might affect immune function, infectious morbidity, growth, cardiometabolic health, neurodevelopment, mitochondrial function, or cancer risk from infancy through adulthood. Furthermore, long-term investigation of potential HIV- and/or ARV-related toxicities is required, especially as antiretroviral therapy (ART) for pregnant people with HIV evolves. It is important to include information about perinatal exposure to HIV and ARV agents in the long-term medical record of a child without HIV in the event that the child develops unusual symptoms later in life or adverse late effects of HIV or ARV exposure in children without HIV are identified in the future.<sup>1-3</sup>

## Potential Increased Morbidity and Mortality

In general, the risks for increased morbidity and mortality are greater in infants who are HIV exposed but uninfected (HEU) than in infants who are HIV unexposed and uninfected (HUU). These differences are more pronounced in infants from low- and middle-income countries than in infants from high-income countries.<sup>4</sup> Higher rates of morbidity and mortality were observed in infants and children in Botswana who were HEU than in those who were HUU, with the strongest predictors of 24-month mortality being HEU status and formula feeding.<sup>5,6</sup> In a meta-analysis, all-cause mortality risk was higher in infants and children who were HEU than in those who were HUU.<sup>7</sup> Further research is needed to confirm these results and to elucidate an immunologic basis for the increased susceptibility of infants and children who were HEU to invasive infections.<sup>8</sup>

## Potential Immunologic Dysfunction and Infectious Morbidity

The potential long-term impact of HIV/ARV exposure on the immune system of an infant without HIV is unclear. In a recent meta-analysis, infants who were HEU had a 50% and 70% increased risk for diarrhea and pneumonia, respectively, compared with infants who were HUU in the first 6 months of life,<sup>9</sup> although recent studies in South Africa have not shown increased infectious morbidity at 3 to 5 years of life.<sup>10</sup> The French Perinatal Cohort Group has observed an increased risk of serious bacterial infections with encapsulated organisms in HEU infants born to mothers with HIV with low CD4 T lymphocyte (CD4) cell counts near the time of delivery.<sup>11</sup> In the United States and Canada, rates of hospitalizations early in life have been found to be higher among infants who were HEU than infants who were HUU,<sup>12-14</sup> with respiratory syncytial virus and parainfluenza playing a potential role in these differences.<sup>12,13</sup> In South Africa, studies have reported higher rates of lower respiratory tract and diarrheal illnesses in the first 6 months of life, as well as infectious-cause hospitalizations between 1 month to 12 months of age, in infants who were HEU than infants who were HUU.<sup>15,16</sup> A potential association between maternal viral load at delivery and infant immunity also was documented previously where infants who were HEU born to mothers with a viral load >1,000 copies/mL had lower CD4 counts than those born to mothers whose viral load was <50 copies/mL at delivery.<sup>17</sup> Immune phenotyping suggests that exposure to HIV *in utero* may be associated with perturbations in infant CD4 and CD8 cell-mediated immune responses, rather than humoral responses, resulting in T-cell dysfunction and altered vaccine responses in infants who were HEU.<sup>13,18,19</sup> These observations have been supported by data showing increased monocyte activation and proinflammatory responses with downregulation of genes involved in neutrophil-mediated immunity in infants who were HEU compared with infants who were HUU.<sup>20-26</sup>

## Potential Adverse Growth and Metabolic Outcomes

Similar to patterns of overall morbidity and mortality in infants who were HEU, the effect of *in utero* HIV/ARV exposure on infant and child growth largely has differed between low- and high-income settings.<sup>27-36</sup> Among studies that compared growth in children who were HEU with those who were HUU, a Nigerian study reported compromised growth in those who were HEU, while studies from South Africa, Zambia, Malawi, and Uganda documented persistently lower weight-for-age z-scores (WAZ) and length-for-age z-scores (LAZ) in early childhood, as well as higher rates of stunting (length or height for age z-score <-2) in those who were HEU.<sup>30,33-35,37-40</sup> These changes may reflect disruption to the growth hormone axis in infants who are HEU compared with infants who are HUU.<sup>40</sup> Among studies that included only children who were HEU, a large study in Ethiopia demonstrated that maternal ART at conception was associated with higher rates of stunting in children who were HEU,<sup>32</sup> but another study in Malawi found no such association.<sup>41</sup> However, in a large Danish study of postnatal growth through 5 years of life, no significant differences in WAZ after 2 weeks of life or LAZ after 6 months of life were noted between children who were HEU and a matched comparator group of children who were HUU.<sup>42</sup> Furthermore, the PHACS SMARTT study in the United States noted above-average weight in children who were HEU compared with children in the general pediatric population.<sup>28</sup> This positive relationship may carry potential long-term cardiometabolic risk for children from high-income settings who were HEU. PHACS SMARTT has found high rates of obesity in children and adolescents who were HEU,<sup>43</sup> and obese children and adolescents who were HEU have a greater risk for systolic and diastolic hypertension than obese children and adolescents in the general pediatric population.<sup>44</sup> Although early derangements in fuel utilization and intermediary metabolism have been described in infants who were HEU in the

United States and Africa, the significance of these findings on long-term metabolic health remains unclear.<sup>45-47</sup>

## Potential Neurodevelopmental Outcomes

Studies investigating whether the risk for poor neurodevelopmental outcomes is higher in children who were HEU than in those who were HUU have not been conclusive.<sup>48-52</sup> The heterogeneity of study populations and study designs may further complicate the interpretation of conflicting results from different studies. Several studies found no differences in early neurodevelopment between children who were HEU and those who were HUU.<sup>52-54</sup> However, some studies reported an increased risk for poorer neurodevelopmental outcomes in children who were HEU.<sup>49-51,53-57</sup> In a recent study from Nairobi, Kenya, HEU children had significantly lower mean z-scores for global cognitive ability than HUU children, as well as short-term and delayed memory, attention, and processing speed, even after adjusting for child nutritional status, household food security, and orphanhood.<sup>58</sup> Among a large cohort of 3- to 6-year-old HEU children from eastern/southern Africa, group-mean composite neurodevelopmental scores averaged within the low-normal range; with differences noted by country and maternal clinical and socioeconomic factors.<sup>59</sup> These data may reflect recent findings documenting lower caudate and total grey matter volumes in HEU infants than HUU infants in the first weeks of life. Furthermore, maternal immunosuppression was associated with reduced caudate and grey matter volumes. These findings suggest that antenatal HIV exposure may impact early structural brain development.<sup>60</sup>

Some studies evaluated whether maternal factors or *in utero* ARV drug exposure contributed to adverse neurodevelopmental outcomes among children who were HEU. Although delayed infant neurodevelopment was associated with maternal viremia in one study,<sup>61</sup> and with *in utero* efavirenz exposure in another,<sup>62</sup> many studies have not identified associations between maternal ARV use and infant neurodevelopment.<sup>56,61,63-65</sup>

In the PHACS SMARTT study, children who were HEU with *in utero* exposure to efavirenz had a greater risk of microcephaly than those without *in utero* efavirenz exposure (see [Efavirenz](#)). Neurodevelopmental assessments at ages 1 year and 5 years demonstrated that children who were HEU with microcephaly had lower mean scores and a higher prevalence of neurodevelopmental impairment than children who were HEU without microcephaly.<sup>66,67</sup> Presently, no definitive evidence shows an association between *in utero* exposure to specific ARV drugs and poorer neurodevelopmental outcomes.<sup>68</sup>

## Potential Mitochondrial Toxicity

Nucleoside reverse transcriptase inhibitor (NRTI) drugs induce some degree of mitochondrial dysfunction, reflecting varying affinity for mitochondrial gamma DNA polymerase. This affinity can interfere with mitochondrial replication, resulting in mitochondrial DNA (mtDNA) depletion and dysfunction.<sup>69-71</sup> Aberrant morphology of mitochondria, mtDNA mutations, alterations in mtDNA levels in cord blood mononuclear cells, and even aneuploidy in cord blood cells have all been described in neonates and young children exposed *in utero* to NRTI drugs.<sup>2,72-74</sup> The degree to which these documented mitochondrial abnormalities are clinically relevant is unknown, but they are outweighed significantly by the robust, proven efficacy of maternal and infant ARV prophylaxis in preventing perinatal HIV transmission.<sup>2,75</sup> In addition, newer NRTIs, such as tenofovir, have not been associated with the same degree of mitochondrial toxicity as older NRTIs, such as zidovudine, lamivudine, and abacavir.<sup>70,76,77</sup>

Although early studies from the French Perinatal Study Group cohort noted a significantly increased incidence of clinical effects reflecting either established or possible mitochondrial dysfunction,<sup>78,79</sup> further clinical studies from the United States and Europe did not corroborate findings from the French studies.<sup>80-86</sup> Some small alterations in mtDNA and oxidative phosphorylation enzyme activities were documented in stored specimens from children who were HEU in the U.S. PACTG 219/219C trial, but the clinical significance of these observations is unknown.<sup>87-89</sup> Mitochondrial dysfunction **may** be considered in children without HIV but with perinatal exposure to ARV drugs who present with clinical findings of unknown etiology, particularly **metabolic or** neurologic findings.

## Potential Cancer Risk and Exposure to NRTI Drugs

Animal studies have reported potential transplacental genotoxicity of nucleoside analogue therapy in monkeys, and micro-nucleated erythrocytes have been identified in infants with *in utero* nucleoside analogue exposure.<sup>90,91</sup> A report from the French Perinatal Cohort described 21 cancers among 15,163 children without HIV (median age 9.9 years) exposed *in utero* to HIV and at least one NRTI drug.<sup>92,93</sup> Among the NRTIs studied, didanosine (**no longer recommended**) potentially was associated with risk of cancer. In a study in the United States, four cancer diagnoses occurred among 3,087 children exposed to HIV; the number of cancer cases did not differ significantly from the number of cases expected based on national reference rates.<sup>94</sup> Continued follow-up of children who were HIV and ARV exposed but uninfected is needed to evaluate the potential risk of cancer as these children age into adulthood.

## Conclusion

In the United States, ongoing evaluation of the early and late effects of *in utero* exposure to ARV drugs and of infant feeding practices is occurring in the PHACS SMARTT study, natural history studies, and HIV/AIDS surveillance conducted by state health departments, as well as the Centers for Disease Control and Prevention. It is critical that studies to evaluate potential adverse effects of *in utero* drug exposure continue to be supported, given the fast pace at which newly developed ARV drugs are being made available to pregnant people who have HIV. HIV surveillance databases from states that require HIV reporting provide an opportunity to collect population-based information concerning *in utero* exposure to ARV drugs. To the extent permitted by federal law and regulations, the data from these confidential registries can be compared with information from birth defects and cancer registries to identify potential adverse outcomes of *in utero* ARV drug exposure.

## References

1. Mofenson LM, Watts DH. Safety of pediatric HIV elimination: the growing population of HIV- and antiretroviral-exposed but uninfected infants. *PLoS Med*. 2014;11(4):e1001636. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24781352>.
2. Jao J, Abrams EJ. Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed Infants. *Pediatr Infect Dis J*. 2014;33(7):734-740. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24378947>.
3. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. *Annu Rev Med*. 2010;61:169-185. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19622036>.
4. Yeganeh N, Watts DH, Xu J, et al. Infectious morbidity, mortality and nutrition in HIV-exposed, uninfected, formula-fed infants: results from the HPTN 040/PACTG 1043 trial. *Pediatr Infect Dis J*. 2018;37(12):1271-1278. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29750766>.
5. Dryden-Peterson S, Ramos T, Shapiro R, Lockman S. Maternal ART and hospitalization or death among HIV-exposed uninfected infants. Presented at: Conference on Retroviruses and Opportunistic Infections, 2016. Seattle, WA.
6. Ajibola G, Leidner J, Mayondi GK, et al. HIV exposure and formula feeding predict under-2 mortality in HIV-uninfected children, Botswana. *J Pediatr*. 2018;203:68-75 e62. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30318370>.
7. Brennan AT, Bonawitz R, Gill CJ, et al. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. *AIDS*. 2016;30(15):2351-2360. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27456985>.
8. Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. *Front Immunol*. 2016;7:310. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27594857>.
9. Brennan AT, Bonawitz R, Gill CJ, et al. A meta-analysis assessing diarrhea and pneumonia in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. *J Acquir Immune Defic Syndr*. 2019;82(1):1-8. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31408450>.
10. Rotheram-Borus MJ, Wynn A, Stewart J, et al. Outcomes of HIV-exposed but uninfected children in South Africa over 5 years. *AIDS*. 2021;35(2):347-349. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33394675>.
11. Taron-Brocard C, Le Chenadec J, Faye A, et al. Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a



- European country. *Clin Infect Dis*. 2014;59(9):1332-1345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25053719>.
12. Labuda SM, Huo Y, Kacanek D, et al. Rates of hospitalization and infection-related hospitalization among human immunodeficiency virus (HIV)-exposed uninfected children compared to HIV-unexposed uninfected children in the United States, 2007–2016. *Clin Infect Dis*. 2020;71(2):332-339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31504291>.
  13. Smith C, Huo Y, Patel K, et al. Immunologic and virologic factors associated with hospitalization in human immunodeficiency virus-exposed, uninfected infants in the United States. *Clin Infect Dis*. 2021;73(6):1089-1096. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34157096>.
  14. Li SNJ, Albert A, Piske M, et al. Higher hospitalization rates in children born HIV-exposed uninfected in British Columbia, Canada, between 1990 and 2012. *Pediatr Infect Dis J*. 2022;41(2):124-130. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34711783>.
  15. le Roux SM, Abrams EJ, Donald KA, et al. Infectious morbidity of breastfed, HIV-exposed uninfected infants under conditions of universal antiretroviral therapy in South Africa: a prospective cohort study. *Lancet Child Adolesc Health*. 2020;4(3):220-231. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31932246>.
  16. Anderson K, Kalk E, Madlala HP, et al. Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed. *AIDS*. 2021;35(14):2327-2339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34324450>.
  17. Kakkar F, Lamarre V, Ducruet T, et al. Impact of maternal HIV-1 viremia on lymphocyte subsets among HIV-exposed uninfected infants: protective mechanism or immunodeficiency. *BMC Infect Dis*. 2014;14:236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24885498>.
  18. Kidzeru EB, Hesseling AC, Passmore JA, et al. In-utero exposure to maternal HIV infection alters T-cell immune responses to vaccination in HIV-uninfected infants. *AIDS*. 2014;28(10):1421-1430. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24785950>.
  19. Jalbert E, Williamson KM, Kroehl ME, et al. HIV-exposed uninfected infants have increased regulatory T cells that correlate with decreased T cell function. *Front Immunol*. 2019;10:595. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30972079>.
  20. Schoeman JC, Moutloatse GP, Harms AC, et al. Fetal metabolic stress disrupts immune homeostasis and induces proinflammatory responses in human immunodeficiency virus type 1- and combination antiretroviral therapy-exposed infants. *J Infect Dis*. 2017;216(4):436-446. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28633455>.
  21. Evans C, Chasekwa B, Rukobo S, et al. Inflammation, CMV and the growth hormone axis in HIV-exposed uninfected infants. Abstract 873. Presented at: Conference on Retroviruses and Opportunistic Infections, 2018. Boston, Massachusetts. Available at:

<http://www.croiconference.org/sessions/inflammation-cmv-and-growth-hormone-axis-hiv-exposed-uninfected-infants>.

22. Mussi-Pinhata MM, Weinberg A, Yu Q, et al. Increased inflammation and monocyte activation in HIV-exposed uninfected infants. Abstract 880. Presented at: Conference on Retroviruses and Opportunistic Infections, 2018, Boston, Massachusetts. Available at: <http://www.croiconference.org/sessions/increased-inflammation-and-monocyte-activation-hiv-exposed-uninfected-infants-0>.
23. Broncano PG, Kgole SW, Masasa G, et al. Innate immune activation among HIV-1 exposed uninfected infants from Botswana. Abstract 881. Presented at: Conference on Retroviruses Opportunistic Infections, 2018, Boston, Massachusetts. Available at: <http://www.croiconference.org/sessions/innate-immune-activation-among-hiv-1-exposed-uninfected-infants-botswana>.
24. Mitchell C, Dominguez S, George V, et al. Microbial translocation, immune activation, and gut dysbiosis in HIV-exposed infants. Abstract 882. Presented at: Conference on Retroviruses and Opportunistic Infections, 2018, Boston, Massachusetts. Available at: <http://www.croiconference.org/sessions/microbial-translocation-immune-activation-and-gut-dysbiosis-hiv-exposed-infants-0>.
25. Dirajlal-Fargo S, Mussi-Pinhata MM, Weinberg A, et al. HIV-exposed-uninfected infants have increased inflammation and monocyte activation. *AIDS*. 2019;33(5):845-853. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30649056>.
26. Gabriel B, Medin C, Alves J, et al. Analysis of the TCR repertoire in HIV-exposed but uninfected infants. *Sci Rep*. 2019;9(1):11954. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31420576>.
27. Musimbi ZD, Rono MK, Otieno JR, et al. Peripheral blood mononuclear cell transcriptomes reveal an over-representation of down-regulated genes associated with immunity in HIV-exposed uninfected infants. *Sci Rep*. 2019;9(1):18124. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31792230>.
28. Neri D, Somarriba GA, Schaefer NN, et al. Growth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States national standards. *J Pediatr*. 2013;163(1):249-254 e241-242. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23360565>.
29. Jacobson DL, Patel K, Williams PL, et al. Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation. *Pediatr Infect Dis J*. 2017;36(2):189-197. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27798548>.
30. Sudfeld CR, Lei Q, Chinyanga Y, et al. Linear growth faltering among HIV-exposed uninfected children. *J Acquir Immune Defic Syndr*. 2016;73(2):182-189. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27116046>.

31. Aizire J, Sikorskii A, Ogwang LW, et al. Decreased growth among antiretroviral drug and HIV-exposed uninfected versus unexposed children in Malawi and Uganda. *AIDS*. 2020;34(2):215-225. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31634154>.
32. Ejigu Y, Magnus JH, Sundby J, Magnus MC. Differences in growth of HIV-exposed uninfected infants in Ethiopia according to timing of in-utero antiretroviral therapy exposure. *Pediatr Infect Dis J*. 2020;39(8):730-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32516280>.
33. Lane CE, Widen EM, Collins SM, Young SL. HIV-exposed, uninfected infants in Uganda experience poorer growth and body composition trajectories than HIV-unexposed infants. *J Acquir Immune Defic Syndr*. 2020;85(2):138-147. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32604132>.
34. Pillay L, Moodley D, Emel LM, Nkwanyana NM, Naidoo K. Growth patterns and clinical outcomes in association with breastfeeding duration in HIV exposed and unexposed infants: a cohort study in KwaZulu Natal, South Africa. *BMC Pediatr*. 2021;21(1):183. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33874900>.
35. Fowler MG, Aizire J, Sikorskii A, et al. Growth deficits in antiretroviral and HIV exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months-of-age. *AIDS*. 2021. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34750297>.
36. Chilyabanyama ON, Chilengi R, Laban NM, et al. Comparing growth velocity of HIV exposed and non-exposed infants: an observational study of infants enrolled in a randomized control trial in Zambia. *PLoS One*. 2021;16(8):e0256443. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34424916>.
37. Jumare J, Datong P, Osawe S, et al. Compromised growth among HIV-exposed uninfected compared with unexposed children in Nigeria. *Pediatr Infect Dis J*. 2019;38(3):280-286. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30418356>.
38. le Roux SM, Abrams EJ, Donald KA, et al. Growth trajectories of breastfed HIV-exposed uninfected and HIV-unexposed children under conditions of universal maternal antiretroviral therapy: a prospective study. *Lancet Child Adolesc Health*. 2019;3(4):234-244. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30773459>.
39. Nyemba DC, Kalk E, Vinikoor MJ, et al. Growth patterns of infants with in-utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia. *BMC Public Health*. 2022;22(1):55. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35000577>.
40. Evans C, Chasekwa B, Ntozini R, et al. Mortality, human immunodeficiency virus (HIV) transmission, and growth in children exposed to HIV in rural Zimbabwe. *Clin Infect Dis*. 2021;72(4):586-594. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31974572>.
41. Toledo G, Landes M, van Lettow M, et al. No difference in growth outcomes up to 24 months of age by duration of exposure to maternal antiretroviral therapy among children



who are HIV-exposed and uninfected in Malawi. *Front Pediatr*. 2022;10:882468. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35795331>.

42. Moseholm E, Helleberg M, Sandholdt H, et al. Children exposed or unexposed to human immunodeficiency virus: weight, height, and body mass index during the first 5 years of life—a Danish nationwide cohort. *Clin Infect Dis*. 2020;70(10):2168-2177. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31271208>.
43. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. *Am J Clin Nutr*. 2011;94(6):1485-1495. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22049166>.
44. Jao J, Jacobson DL, Yu W, et al. A comparison of metabolic outcomes between obese HIV-exposed uninfected youth from the PHACS SMARTT study and HIV-unexposed youth from the NHANES study in the United States. *J Acquir Immune Defic Syndr*. 2019;81(3):319-327. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30844997>.
45. Kirmse B, Hobbs CV, Peter I, et al. Abnormal newborn screens and acylcarnitines in HIV-exposed and ARV-exposed infants. *Pediatr Infect Dis J*. 2013;32(2):146-150. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22935866>.
46. Jao J, Kirmse B, Yu C, et al. Lower preprandial insulin and altered fuel use in HIV/antiretroviral-exposed infants in Cameroon. *J Clin Endocrinol Metab*. 2015;100(9):3260-3269. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26133363>.
47. Jao J, Balmert LC, Sun S, et al. Distinct cord blood C-peptide, adipokine, and lipidomic signatures by in utero HIV exposure. *Pediatr Res*. 2021. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34446848>.
48. McHenry MS, McAteer CI, Oyungu E, et al. Neurodevelopment in young children born to HIV-infected mothers: a meta-analysis. *Pediatrics*. 2018;141(2). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29374109>.
49. Madlala HP, Myer L, Malaba TR, Newell ML. Neurodevelopment of HIV-exposed uninfected children in Cape Town, South Africa. *PLoS One*. 2020;15(11):e0242244. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33206724>.
50. Sevenoaks T, Wedderburn CJ, Donald KA, et al. Association of maternal and infant inflammation with neurodevelopment in HIV-exposed uninfected children in a South African birth cohort. *Brain Behav Immun*. 2021;91:65-73. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32860940>.
51. White M, Connor KL. *In utero* HIV exposure and the early nutritional environment influence infant neurodevelopment: findings from an evidenced review and meta-analysis. *Nutrients*. 2020;12(11). Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33147767>.

52. Zhang X, Wang L, Han J, et al. In utero antiretroviral exposure and sociodemographic characteristics on neurodevelopment of HIV-exposed uninfected children versus HIV-unexposed uninfected healthy children in Malawi. *Int J Gynaecol Obstet*. 2021;153(3):424-437. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33270235>.
53. Kerr SJ, Puthanakit T, Vibol U, et al. Neurodevelopmental outcomes in HIV-exposed-uninfected children versus those not exposed to HIV. *AIDS Care*. 2014;26(11):1327-1335. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24878112>.
54. Springer PE, Slogrove AL, Kidd M, et al. Neurodevelopmental and behavioural outcomes of HIV-exposed uninfected and HIV-unexposed children at 2-3 years of age in Cape Town, South Africa. *AIDS Care*. 2020;32(4):411-419. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31280587>.
55. Wedderburn CJ, Yeung S, Rehman AM, et al. Neurodevelopment of HIV-exposed uninfected children in South Africa: outcomes from an observational birth cohort study. *Lancet Child Adolesc Health*. 2019;3(11):803-813. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31515160>.
56. Piske M, Budd MA, Qiu AQ, et al. Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children. *AIDS*. 2018;32(17):2583-2592. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30134292>.
57. Ntozini R, Chandna J, Evans C, et al. Early child development in children who are HIV-exposed uninfected compared to children who are HIV-unexposed: observational sub-study of a cluster-randomized trial in rural Zimbabwe. *J Int AIDS Soc*. 2020;23(5):e25456. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32386127>.
58. Benki-Nugent SF, Yunusa R, Mueni A, et al. Lower neurocognitive functioning in HIV-exposed uninfected children compared with that in HIV-unexposed children. *J Acquir Immune Defic Syndr*. 2022;89(4):441-447. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35202050>.
59. Fowler MG, Hanrahan C, Yende N, et al. Neurodevelopmental outcomes of HIV/antiretroviral drug perinatally exposed uninfected children aged 3-6 years. *AIDS*. 2022;36(11):1533-1543. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35730383>.
60. Wedderburn CJ, Ringshaw JE, Donald KA, et al. Association of maternal and child anemia with brain structure in early life in South Africa. *JAMA Netw Open*. 2022;5(12):e2244772. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36459137>.
61. le Roux SM, Donald KA, Kroon M, et al. HIV viremia during pregnancy and neurodevelopment of HIV-exposed uninfected children in the context of universal antiretroviral therapy and breastfeeding: a prospective study. *Pediatr Infect Dis J*. 2019;38(1):70-75. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30234792>.
62. Cassidy AR, Williams PL, Leidner J, et al. In utero efavirenz exposure and neurodevelopmental outcomes in HIV-exposed uninfected children in Botswana. *Pediatr*

- Infect Dis J.* 2019;38(8):828-834. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30985518>.
63. Chaudhury S, Mayondi GK, Williams PL, et al. In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana. *AIDS*. 2018;32(9):1173-1183. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29547434>.
  64. Kacanek D, Williams PL, Mayondi G, et al. Pediatric neurodevelopmental functioning after in utero exposure to triple-NRTI vs. dual-NRTI + PI ART in a randomized trial, Botswana. *J Acquir Immune Defic Syndr*. 2018;79(3):e93-e100. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30015793>.
  65. Williams PL, Marino M, Malee K, et al. Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants. *Pediatrics*. 2010;125(2):e250-260. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20083530>.
  66. Williams PL, Yildirim C, Chadwick EG, et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. *Lancet HIV*. 2020;7(1):e49-e58. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31740351>.
  67. le Roux SM, Abrams EJ. Efavirenz in pregnancy. *Lancet HIV*. 2019;7(1):e6-e8. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31740349>.
  68. Crowell CS, Williams PL, Yildirim C, et al. Safety of in-utero antiretroviral exposure: neurologic outcomes in children who are HIV-exposed but uninfected. *AIDS*. 2020;34(9):1377-1387. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32310900>.
  69. Brinkman K, Ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. *AIDS*. 1998;12(14):1735-1744. Available at: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list\\_uids=9792373&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9792373&dopt=Abstract).
  70. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother*. 2002;46(3):716-723. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11850253>.
  71. Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. *Antimicrob Agents Chemother*. 2008;52(8):2825-2830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18541728>.
  72. Jao J, Powis KM, Kirmse B, et al. Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in cameroon. *AIDS*. 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28926411>.

73. Budd MA, Calli K, Samson L, et al. Blood mitochondrial DNA content in HIV-exposed uninfected children with autism spectrum disorder. *Viruses*. 2018;10(2):77. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29439467>.
74. Ajaykumar A, Zhu M, Kakkar F, et al. Blood mitochondrial DNA levels remain elevated from birth to early life in children HIV-exposed uninfected exposed to combination antiretroviral therapy in utero. *J Infect Dis*. 2020;jiaa410. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32638023>.
75. Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. *Curr Opin HIV AIDS*. 2013;8(5):504-510. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23743789>.
76. Stray KM, Park Y, Babusis D, et al. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. *Antiviral Res*. 2017;140:116-120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28131805>.
77. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. *Antiviral Res*. 2002;54(1):37-45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11888656>.
78. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. *Lancet*. 1999;354(9184):1084-1089. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10509500>.
79. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. *AIDS*. 2003;17(12):1769-1785. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12891063>.
80. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 study. *AIDS*. 1998;12(14):1805-1813. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9792381>.
81. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. *J Acquir Immune Defic Syndr*. 2000;25(3):261-268. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11115957>.
82. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. *N Engl J Med*. 2000;343(11):759-766. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10984563>.
83. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. *J Acquir Immune Defic*

- Syndr.* 2003;32(4):380-387. Available at:  
[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list\\_uids=12640195&dopt=Abstract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12640195&dopt=Abstract).
84. Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. *Pediatrics*. 2006;118(4):e1139-1145. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/16940166>.
  85. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. *AIDS*. 2007;21(8):929-938. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17457086>.
  86. Hankin C, Lyall H, Peckham C, Tookey P. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. *AIDS*. 2007;21(7):867-869. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17415042>.
  87. Brogly SB, DiMauro S, Van Dyke RB, et al. Short communication: transplacental nucleoside analogue exposure and mitochondrial parameters in HIV-uninfected children. *AIDS Res Hum Retroviruses*. 2011;27(7):777-783. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/21142587>.
  88. Brogly SB, Foca M, Deville JG, et al. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. *J Acquir Immune Defic Syndr*. 2010;53(1):154-157. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/20035168>.
  89. Desquiret-Dumas V, D'Ottavi M, Monnin A, et al. Long-term persistence of mitochondrial DNA instability in HIV-exposed uninfected children during and after exposure to antiretroviral drugs and HIV. *Biomedicines*. 2022;10(8). Available at:  
<https://www.ncbi.nlm.nih.gov/pubmed/35892686>.
  90. Olivero OA, Fernandez JJ, Antiochos BB, Wagner JL, St Claire ME, Poirier MC. Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in *Erythrocebus patas* monkeys. *J Acquir Immune Defic Syndr*. 2002;29(4):323-329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11917235>.
  91. Witt KL, Cunningham CK, Patterson KB, et al. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. *Environ Mol Mutagen*. 2007;48(3-4):322-329. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/17358032>.
  92. Hleyhel M, Goujon S, Delteil C, et al. Risk of cancer in children exposed to didanosine in utero. *AIDS*. 2016;30(8):1245-1256. Available at:  
<http://www.ncbi.nlm.nih.gov/pubmed/26854809>.



93. Hleyhel M, Goujon S, Sibiude J, et al. Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: the French experience. *Environ Mol Mutagen*. 2019;60(5):404-409. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29206312>.
94. Ivy W, 3rd, Nesheim SR, Paul SM, et al. Cancer among children with perinatal exposure to HIV and antiretroviral medications—New Jersey, 1995–2010. *J Acquir Immune Defic Syndr*. 2015;70(1):62-66. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26017660>.